Xcell Therapeutics Balance Sheet Health
Financial Health criteria checks 0/6
Xcell Therapeutics has a total shareholder equity of ₩161.2M and total debt of ₩5.7B, which brings its debt-to-equity ratio to 3517.9%. Its total assets and total liabilities are ₩10.1B and ₩9.9B respectively.
Key information
3,517.9%
Debt to equity ratio
₩5.67b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩1.02b |
| Equity | ₩161.18m |
| Total liabilities | ₩9.89b |
| Total assets | ₩10.06b |
Recent financial health updates
No updates
Recent updates
No updates
Financial Position Analysis
Short Term Liabilities: A373110's short term assets (₩2.7B) do not cover its short term liabilities (₩7.0B).
Long Term Liabilities: A373110's short term assets (₩2.7B) do not cover its long term liabilities (₩2.9B).
Debt to Equity History and Analysis
Debt Level: A373110's net debt to equity ratio (2884.1%) is considered high.
Reducing Debt: Insufficient data to determine if A373110's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A373110 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: A373110 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 2.4% each year